Creating new treatments for acute leukemia by targeting specific genes
Development of ASH1L inhibitors for acute leukemia
This study is looking at a new way to help people with acute myeloid leukemia (AML) by testing a treatment that targets a specific protein to lower the activity of certain genes linked to the disease, and patients may have the chance to participate in trials to see how well this treatment works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10740903 on NIH RePORTER |
What this research studies
This research focuses on developing inhibitors that target the ASH1L protein, which plays a crucial role in the expression of HOX genes linked to acute leukemia. By reducing the expression of these genes, the research aims to create a novel treatment strategy for patients suffering from acute myeloid leukemia (AML), a condition with a low survival rate. The approach involves using small molecules to inhibit ASH1L, which has shown promise in preclinical studies. Patients may be involved in clinical trials to test the effectiveness and safety of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia (AML) who have high levels of HOX gene expression.
Not a fit: Patients with other types of leukemia or those who do not have high HOX gene expression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for acute leukemia, potentially improving survival rates and patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting HOX gene dysregulation in leukemia, suggesting that this approach could be a viable treatment strategy.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Grembecka, Jolanta — University of Michigan at Ann Arbor
- Study coordinator: Grembecka, Jolanta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.